Evidence map›Paper›PMID 40253667›Full record

ArticleEuropean journal of trauma and emergency surgery : official publication of the European Trauma Society2025

Immunomodulatory and cardio-protective effects of differentially originated multipotent mesenchymal stroma cells during polymicrobial sepsis in mice.

Anna Kanewska, Ina Lackner, Anne Friedrich, Martina Winkelmann, Markus Rojewski, Birte Weber, Jochen Preßmar, Mario Perl, Hubert Schrezenmeier, Miriam Kalbitz

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European journal of trauma and emergency surgery : official publication of the European Trauma Society, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Therapeutical progress in sepsis-induced cardiomyopathy.Frontiers in cardiovascular medicine · 2026
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Anna Kanewska *Department of Trauma and Orthopedic Surgery, University Hospital Erlangen Friedrich-Alexander Universität Erlangen-Nürnberg (FAU), Erlangen, Germany. anna.kanewska@gmail.com.
Ina Lackner *Department of Trauma and Orthopedic Surgery, University Hospital Erlangen Friedrich-Alexander Universität Erlangen-Nürnberg (FAU), Erlangen, Germany.
Anne Friedrich *Department of Trauma and Orthopedic Surgery, University Hospital Erlangen Friedrich-Alexander Universität Erlangen-Nürnberg (FAU), Erlangen, Germany.
Martina WinkelmannInstitute for Transfusion Medicine, University Medical Center Ulm, Ulm, Germany.
Markus RojewskiInstitute for Transfusion Medicine, University Medical Center Ulm, Ulm, Germany.
Birte WeberDepartment of Trauma Surgery and Orthopedics, University Hospital Frankfurt, Goethe-University, Frankfurt Am Main, Germany.
Jochen PreßmarDepartment of Trauma and Orthopedic Surgery, University Hospital Erlangen Friedrich-Alexander Universität Erlangen-Nürnberg (FAU), Erlangen, Germany.
Mario PerlDepartment of Trauma and Orthopedic Surgery, University Hospital Erlangen Friedrich-Alexander Universität Erlangen-Nürnberg (FAU), Erlangen, Germany.
Hubert SchrezenmeierInstitute for Transfusion Medicine, University Medical Center Ulm, Ulm, Germany.
Miriam KalbitzDepartment of Trauma and Orthopedic Surgery, University Hospital Erlangen Friedrich-Alexander Universität Erlangen-Nürnberg (FAU), Erlangen, Germany.

Funding

Deutsche Forschungsgemeinschaft 493624887
6 · The paper itself

Abstract

purposeSepsis is a life-threatening condition with cardiac complications being an independent predictor of poor outcome. Although their mechanisms have been widely investigated, therapeutic options remain limited. One promising therapeutic tool are mesenchymal stromal cells (MSCs). The aim of this study is to investigate the immunomodulatory effects of human MSCs from two different sources (bone marrow/BMMSC and adipose tissue/ASC) and to evaluate their cardioprotective potential.

methods60 adult male C57BL/6 mice were divided into sham, sepsis (cecal ligation puncture (CLP)) and two i.v. treatment groups CLP + human BMMSC and CLP + human ASC with 5 animals in each group. The observation periods were 8, 24 and 72 h. Left ventricular tissue was analyzed histologically, by qPCR (C3ar, C5ar1, Il-1b, Il-6, Il-10, Tlr2, Tlr4, Tnfa, and Nlrp3) and western blot. Cardiac damage markers troponin I and heart fatty acid binding protein (HFABP) were detected in serum by ELISA.

resultsTroponin I and HFABP were significantly increased in CLP group after 8 h compared to sham. In cardiac tissue the expression of C3ar, C5ar1, Il-1b, Il-6, Il-10, Tlr2, Tlr4, Tnfa and Nlrp3 inflammasome was upregulated up to 24h after CLP compared to sham. After BMMSC treatment, C3ar as well as C5ar, Tlr2 and Il-10 mRNA expression in left ventricle was downregulated compared to CLP, whereas ASC treatment was associated with the downregulation of Il-6 and Nlrp3.

conclusionsCLP-induced polymicrobial sepsis in mice was associated with cardiac damage and increased inflammation in left ventricular tissue. Therapeutic systemic application of human BMMSC and ASC ameliorated damage and inflammation in the heart.

Indexed as

Mesenchymal Stem CellsMesenchymal Stem Cell TransplantationSepsisAdipose TissueAnimalsDisease Models, AnimalFatty Acid-Binding ProteinsHumansImmunomodulationMaleMiceMice, Inbred C57BLTroponin IFatty Acid-Binding ProteinsTroponin IASC treatmentBMMSC treatmentCardiac dysfunctionCLP sepsisImmunotherapySeptic cardiomyopathyTissue regeneration

Identifiers

PMID40253667
PMCPMC12009780

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.